Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase I-II clinical study

Giammaria Fiorentini, Susanna Rossi, Patrizia Dentico, Francesco Meucci, Francesco Bonechi, Paolo Bernardeschi, Maurizio Cantore, Stefano Guadagni, Michele De Simone

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Oxaliplatin is a new drug active in the treatment of advanced colorectal cancer. Hepatic arterial infusion chemotherapy is under evaluation because of the high target dose and low general toxicity. Twelve patients with liver metastases from colorectal cancer were enrolled, all pretreated with evidence of progressive disease: three after a partial remission induced by oxaliplatin, folinic acid and 5-FU, three patients after a partial remission induced by irinotecan, folinic acid and 5-FU and six patients after failing a 5-FU and folinic acid regimen. They received hepatic arterial infusion chemotherapy with oxaliplatin as 30-min infusion on an out-patient basis every 3 weeks. Dose-limiting toxicity was observed at 175 mg/m 2/cycle and consisted of obliteration of the hepatic artery in one patient, abdominal pain requiring morphine in one patient and severe hypotension requiring plasma expander in a third. Following phase I, all patients received 150 mg/m 2 for six cycles. We reported four cases of partial remission (33%) lasting 24, 15, 12 and 10+ weeks, respectively, 2 stabilisation of disease (17%) lasting more than 12 weeks and six progressions (50%). Six patients (50%) presented CEA reduction of >30% and five patients (41%) showed an increase of >8% of body weight. The median survival was 13 months (range 6-19). Oxaliplatin did not present significant toxicity for liver parenchyma and biliary tree. We advise that further studies be undertaken with oxaliplatin 150 mg/m 2.

Original languageEnglish
Pages (from-to)2093-2096
Number of pages4
JournalAnticancer Research
Volume24
Issue number3 B
Publication statusPublished - May 2004

Fingerprint

oxaliplatin
Colorectal Neoplasms
Neoplasm Metastasis
Drug Therapy
Liver
Leucovorin
Fluorouracil
irinotecan
Clinical Studies
Hepatic Artery
Biliary Tract

Keywords

  • Hepatic arterial infusion chemotherapy
  • Liver metastases from colorectal cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fiorentini, G., Rossi, S., Dentico, P., Meucci, F., Bonechi, F., Bernardeschi, P., ... De Simone, M. (2004). Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase I-II clinical study. Anticancer Research, 24(3 B), 2093-2096.

Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer : A phase I-II clinical study. / Fiorentini, Giammaria; Rossi, Susanna; Dentico, Patrizia; Meucci, Francesco; Bonechi, Francesco; Bernardeschi, Paolo; Cantore, Maurizio; Guadagni, Stefano; De Simone, Michele.

In: Anticancer Research, Vol. 24, No. 3 B, 05.2004, p. 2093-2096.

Research output: Contribution to journalArticle

Fiorentini, G, Rossi, S, Dentico, P, Meucci, F, Bonechi, F, Bernardeschi, P, Cantore, M, Guadagni, S & De Simone, M 2004, 'Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase I-II clinical study', Anticancer Research, vol. 24, no. 3 B, pp. 2093-2096.
Fiorentini G, Rossi S, Dentico P, Meucci F, Bonechi F, Bernardeschi P et al. Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase I-II clinical study. Anticancer Research. 2004 May;24(3 B):2093-2096.
Fiorentini, Giammaria ; Rossi, Susanna ; Dentico, Patrizia ; Meucci, Francesco ; Bonechi, Francesco ; Bernardeschi, Paolo ; Cantore, Maurizio ; Guadagni, Stefano ; De Simone, Michele. / Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer : A phase I-II clinical study. In: Anticancer Research. 2004 ; Vol. 24, No. 3 B. pp. 2093-2096.
@article{ca58c3f0be934cf686c7530ece739a0d,
title = "Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase I-II clinical study",
abstract = "Oxaliplatin is a new drug active in the treatment of advanced colorectal cancer. Hepatic arterial infusion chemotherapy is under evaluation because of the high target dose and low general toxicity. Twelve patients with liver metastases from colorectal cancer were enrolled, all pretreated with evidence of progressive disease: three after a partial remission induced by oxaliplatin, folinic acid and 5-FU, three patients after a partial remission induced by irinotecan, folinic acid and 5-FU and six patients after failing a 5-FU and folinic acid regimen. They received hepatic arterial infusion chemotherapy with oxaliplatin as 30-min infusion on an out-patient basis every 3 weeks. Dose-limiting toxicity was observed at 175 mg/m 2/cycle and consisted of obliteration of the hepatic artery in one patient, abdominal pain requiring morphine in one patient and severe hypotension requiring plasma expander in a third. Following phase I, all patients received 150 mg/m 2 for six cycles. We reported four cases of partial remission (33{\%}) lasting 24, 15, 12 and 10+ weeks, respectively, 2 stabilisation of disease (17{\%}) lasting more than 12 weeks and six progressions (50{\%}). Six patients (50{\%}) presented CEA reduction of >30{\%} and five patients (41{\%}) showed an increase of >8{\%} of body weight. The median survival was 13 months (range 6-19). Oxaliplatin did not present significant toxicity for liver parenchyma and biliary tree. We advise that further studies be undertaken with oxaliplatin 150 mg/m 2.",
keywords = "Hepatic arterial infusion chemotherapy, Liver metastases from colorectal cancer, Oxaliplatin",
author = "Giammaria Fiorentini and Susanna Rossi and Patrizia Dentico and Francesco Meucci and Francesco Bonechi and Paolo Bernardeschi and Maurizio Cantore and Stefano Guadagni and {De Simone}, Michele",
year = "2004",
month = "5",
language = "English",
volume = "24",
pages = "2093--2096",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer

T2 - A phase I-II clinical study

AU - Fiorentini, Giammaria

AU - Rossi, Susanna

AU - Dentico, Patrizia

AU - Meucci, Francesco

AU - Bonechi, Francesco

AU - Bernardeschi, Paolo

AU - Cantore, Maurizio

AU - Guadagni, Stefano

AU - De Simone, Michele

PY - 2004/5

Y1 - 2004/5

N2 - Oxaliplatin is a new drug active in the treatment of advanced colorectal cancer. Hepatic arterial infusion chemotherapy is under evaluation because of the high target dose and low general toxicity. Twelve patients with liver metastases from colorectal cancer were enrolled, all pretreated with evidence of progressive disease: three after a partial remission induced by oxaliplatin, folinic acid and 5-FU, three patients after a partial remission induced by irinotecan, folinic acid and 5-FU and six patients after failing a 5-FU and folinic acid regimen. They received hepatic arterial infusion chemotherapy with oxaliplatin as 30-min infusion on an out-patient basis every 3 weeks. Dose-limiting toxicity was observed at 175 mg/m 2/cycle and consisted of obliteration of the hepatic artery in one patient, abdominal pain requiring morphine in one patient and severe hypotension requiring plasma expander in a third. Following phase I, all patients received 150 mg/m 2 for six cycles. We reported four cases of partial remission (33%) lasting 24, 15, 12 and 10+ weeks, respectively, 2 stabilisation of disease (17%) lasting more than 12 weeks and six progressions (50%). Six patients (50%) presented CEA reduction of >30% and five patients (41%) showed an increase of >8% of body weight. The median survival was 13 months (range 6-19). Oxaliplatin did not present significant toxicity for liver parenchyma and biliary tree. We advise that further studies be undertaken with oxaliplatin 150 mg/m 2.

AB - Oxaliplatin is a new drug active in the treatment of advanced colorectal cancer. Hepatic arterial infusion chemotherapy is under evaluation because of the high target dose and low general toxicity. Twelve patients with liver metastases from colorectal cancer were enrolled, all pretreated with evidence of progressive disease: three after a partial remission induced by oxaliplatin, folinic acid and 5-FU, three patients after a partial remission induced by irinotecan, folinic acid and 5-FU and six patients after failing a 5-FU and folinic acid regimen. They received hepatic arterial infusion chemotherapy with oxaliplatin as 30-min infusion on an out-patient basis every 3 weeks. Dose-limiting toxicity was observed at 175 mg/m 2/cycle and consisted of obliteration of the hepatic artery in one patient, abdominal pain requiring morphine in one patient and severe hypotension requiring plasma expander in a third. Following phase I, all patients received 150 mg/m 2 for six cycles. We reported four cases of partial remission (33%) lasting 24, 15, 12 and 10+ weeks, respectively, 2 stabilisation of disease (17%) lasting more than 12 weeks and six progressions (50%). Six patients (50%) presented CEA reduction of >30% and five patients (41%) showed an increase of >8% of body weight. The median survival was 13 months (range 6-19). Oxaliplatin did not present significant toxicity for liver parenchyma and biliary tree. We advise that further studies be undertaken with oxaliplatin 150 mg/m 2.

KW - Hepatic arterial infusion chemotherapy

KW - Liver metastases from colorectal cancer

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=3242679883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242679883&partnerID=8YFLogxK

M3 - Article

C2 - 15274406

AN - SCOPUS:3242679883

VL - 24

SP - 2093

EP - 2096

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -